---
title: "The flu vaccine has a \"freezing point price\" of 5.5 yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255878857.md"
description: "In September, multiple provinces including Beijing and Zhejiang have successively launched this year's influenza vaccine vaccination work. A piece of news stating that \"the unit price of the public-funded influenza vaccine has dropped to 5.5 yuan\" has attracted industry attention. On September 1 and 2, the National Public Resources Trading Platform (Beijing) successively released the winning announcements for the 2025 Beijing influenza vaccine immunization and non-immunization procurement projects, with HUALAN BIOLOGICAL, Shanghai Institute of Biological Products, and Beijing Kexing being awarded the \"immunization\" project. (Yicai)"
datetime: "2025-09-04T03:21:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255878857.md)
  - [en](https://longbridge.com/en/news/255878857.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255878857.md)
---

# The flu vaccine has a "freezing point price" of 5.5 yuan

In September, multiple provinces including Beijing and Zhejiang have successively launched this year's influenza vaccine vaccination work. A piece of news stating that "the unit price of the public-funded influenza vaccine has dropped to 5.5 yuan" has attracted industry attention. On September 1 and 2, the National Public Resources Trading Platform (Beijing) successively released the bidding announcements for the 2025 Beijing influenza vaccine immunization and non-immunization procurement projects, with HUALAN BIOLOGICAL, Shanghai Institute of Biological Products, and Beijing Kexing winning the "immunization" project. (Yicai)

### Related Stocks

- [002007.CN](https://longbridge.com/en/quote/002007.CN.md)
- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)

## Related News & Research

- [BactiQuant restructures operations, cuts fixed costs 15% to focus on pharma sales](https://longbridge.com/en/news/295512832.md)
- [Spineart wins FDA approval for BAGUERA C cervical disc, GIMV says](https://longbridge.com/en/news/295532273.md)
- [Hyorc Corporation Announces Routine Board Member Resignation](https://longbridge.com/en/news/295435201.md)
- [Keymed Biosciences says Phase II trial of CM512 meets endpoints in chronic rhinosinusitis with nasal polyps](https://longbridge.com/en/news/295337751.md)
- [Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong'](https://longbridge.com/en/news/295482984.md)